Stryker Q3 sales rise 7.6% to $6.52B, but net income falls 12.3% on $293M goodwill impairment

Filed October 30, 2026 · Period ending September 30, 2026 · Compared to 10-Q Oct 31, 2025 · ~1 min read

Key Changes

• high

  Net income fell 12.3% to $753.0M, or $1.96 per diluted share, from $859M, or $2.22, a year earlier, driven by a $293 million goodwill impairment charge for the Peripheral Vascular business.

  MD&A: Results of Operations verify on EDGAR →
• high

  Operating income declined to $1,034 million from $1,135 million, with operating margin dropping to 15.9% from 18.7%, reflecting the impairment and higher structural optimization charges.

  MD&A: Results of Operations verify on EDGAR →
• high

  Board approved a $3 billion increase to the share repurchase program in October 2026, bringing total authorization to $3.033 billion; $1 billion was repurchased during 2026.

  MD&A: Liquidity and Capital Resources verify on EDGAR →